Efficacy and Safety of Continuing Bevacizumab beyond Disease Progression plus Docetaxel in Patients with Non-Small Cell Lung Cancer: A Retrospective Analysis
Background: Bevacizumab-based chemotherapy has
been shown to extend progression-free survival (PFS) of lung cancer, but its
effect on overall survival (OS) remains unclear. However, bevacizumab beyond
disease progression (BBP) significantly improved OS in patients with metastatic
colorectal cancer. Methods: Therefore, we retrospectively analysed 22 patients
with non-small cell lung cancer (NSCLC) who were treated with docetaxel plus
BBP at the Department of Thoracic Oncology, Kansai Medical University Hirakata
Hospital, between November 2009 and March 2013. Results: The response rate was
31.8% and the disease control rate was 86.4%. The median PFS was 4.5 months
(95% confidence interval [CI], 2.5 - 8.7 months) and the median OS was 17.2
months (95% CI, 8.5 - 25.9 months). Grade 3 and 4 adverse events included
leukocytopenia (68.2%), neutropenia (77.3%), fatigue (9.1%), proteinuria
(9.1%), febrile neutropenia (4.5%), anemia (4.5%), and anorexia (4.5%).
Conclusion: Docetaxel plus BBP was found to be generally well tolerated and
effective.
References
[1]
Johnson, D.H., Fehrenbacher, L., Novotny, W.F., Herbst, R.S., Nemunaitis, J.J., Jablons, D.M., Langer, C.J., DeVore 3rd, R.F., Gaudreault, J., Damico, L.A., Holmgren, E. and Kabbinavar, F. (2004) Randomized Phase II Trial Comparing Bevacizumab plus Carboplatin and Paclitaxel with Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 22, 2184-2191.
http://dx.doi.org/10.1200/JCO.2004.11.022
[2]
Sandler, A., Gray, R., Perry, M.C., Brahmer, J., Schiller, J.H., Dowlati, A., Lilenbaum, R. and Johnson, D.H. (2006) Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 355, 2542-2550. http://dx.doi.org/10.1056/NEJMoa061884
[3]
Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N. and Manegold, C. (2009) Phase III Trial of Cisplatin plus Gemcitabine with either Placebo or Bevacizumab as First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAil. Journal of Clinical Oncology, 27, 1227-1234. http://dx.doi.org/10.1200/JCO.2007.14.5466
[4]
Niho, S., Kunitoh, H., Nokihara, H., Horai, T., Ichinose, Y., Hida, T., Yamamoto, N., Kawahara, M., Shinkai, T., Nakagawa, K., Matsui, K., Negoro, S., Yokoyama, A., Kudoh, S., Kiura, K., Mori, K., Okamoto, H., Sakai, H., Takeda, K., Yokota, S., Saijo, N. and Fukuoka, M. (2012) Randomized Phase II Study of First-Line Carboplatin-Paclitaxel with or without Bevacizumab in Japanese Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer. Lung Cancer, 76, 362-367. http://dx.doi.org/10.1016/j.lungcan.2011.12.005
[5]
Mancuso, M.R., Davis, R., Norberg, S.M., O’Brien, S., Sennino, B., Nakahara, T., Yao, V.J., Inai, T., Brooks, P., Freimark, B., Shalinsky, D.R., Hu-Lowe, D.D. and McDonald, D.M. (2006) Rapid Vascular Regrowth in Tumors after Reversal of VEGF Inhibition. Journal of Clinical Investigation, 116, 2610-2621. http://dx.doi.org/10.1172/JCI24612
[6]
Steeghs, N., Rabelink, T.J., op’t Roodt, J., Batman, E., Cluitmans, F.H., Weijl, N.I., de Koning, E. and Gelderblom, H. (2010) Reversibility of Capillary Density after Discontinuation of Bevacizumab Treatment. Annals of Oncology, 21, 1100-1105. http://dx.doi.org/10.1093/annonc/mdp417
[7]
Bennouna, J., Sastre, J., Arnold, D., ?sterlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J.M., Bouché, O., Borg, C., Steffens, C.C., Alonso-Ordu?a, V., Schlichting, C., Reyes-Rivera, I., Bendahmane, B., André, T. and Kubicka, S. (2013) ML18147 Study Investigators. Continuation of Bevacizumab after First Progression in Metastatic Colorectal Cancer (ML18147): A Randomised Phase 3 Trial. The Lancet Oncology, 14, 29-37.
http://dx.doi.org/10.1016/S1470-2045(12)70477-1
[8]
Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D. and Verweij, J. (2009) New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). European Journal of Cancer, 45, 228-247. http://dx.doi.org/10.1016/j.ejca.2008.10.026
[9]
Cancer Therapy Evaluation Program [NCCN Web Site].
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
[10]
Shepherd, F.A., Dancey, J., Ramlau, R., Mattson, K., Gralla, R., O’Rourke, M., Levitan, N., Gressot, L., Vincent, M., Burkes, R., Coughlin, S., Kim, Y. and Berille, J. (2000) Prospective Randomized Trial of Docetaxel versus Best Supportive Care in Patients with Non-Small-Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy. Journal of Clinical Oncology, 18, 2095-2103.
[11]
Fossella, F.V., DeVore, R., Kerr, R.N., Crawford, J., Natale, R.R., Dunphy, F., Kalman, L., Miller, V., Lee, J.S., Moore, M., Gandara, D., Karp, D., Vokes, E., Kris, M., Kim, Y., Gamza, F. and Hammershaimb, L. (2000) Randomized Phase III Trial of Docetaxel versus Vinorelbine or Ifosfamide in Patients with Advanced Non-Small-Cell Lung Cancer Previously Treated with Platinum-Containing Chemotherapy Regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. Journal of Clinical Oncology, 18, 2354-2362.
[12]
Hanna, N., Shepherd, F.A., Fossella, F.V., Pereira, J.R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T.C.Y., Pless, M., Muller, T., Lim, H.L., Desch, C., Szondy, K., Gervais, R., Shaharyar, Manegold, C., Paul, S., Paoletti, P., Einhorn, L. and Bunn Jr., P.A. (2004) Randomized Phase III Trial of Pemetrexed versus Docetaxel in Patients with Non-Small-Cell Lung Cancer Previously Treated with Chemotherapy. Journal of Clinical Oncology, 22, 1589-1597.
http://dx.doi.org/10.1200/JCO.2004.08.163
[13]
Di Maio, M., Chiodini, P., Georgoulias, V., Hatzidaki, D., Takeda, K., Wachters, F.M., Gebbia, V., Smit, E.F., Morabito, A., Gallo, C., Perrone, F. and Gridelli, C. (2009) Meta-Analysis of Single-Agent Chemotherapy Compared with Combination Chemotherapy as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 27, 1836-1843. http://dx.doi.org/10.1200/JCO.2008.17.5844
[14]
Kawaguchi, T., Ando, M., Asami, K., Okano, Y., Fukuda, M., Nakagawa, H., Ibata, H., Kozuki, T., Endo, T., Tamura, A., Kamimura, M., Sakamoto, K., Yoshimi, M., Soejima, Y., Tomizawa, Y., Isa, S., Takada, M., Saka, H. and Kubo, A. (2014) Randomized Phase III Trial of Erlotinib versus Docetaxel as Second- or Third-Line Therapy in Patients with Advanced Non-Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). Journal of Clinical Oncology, 32, 1902-1908. http://dx.doi.org/10.1200/JCO.2013.52.4694
[15]
Takeda, M., Okamoto, I., Yamanaka, T., Nakagawa, K. and Nakanishi, Y. (2012) Impact of Treatment with Bevacizumab beyond Disease Progression: A Randomized Phase II Study of Docetaxel with or without Bevacizumab after Platinum-Based Chemotherapy plus Bevacizumab in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer (WJOG 5910L). BMC Cancer, 12, 327. http://dx.doi.org/10.1186/1471-2407-12-327
[16]
Gridelli, C., Bennouna, J., de Castro, J., Dingemans, A.M., Griesinger, F., Grossi, F., Rossi, A., Thatcher, N., Wong, E.K. and Langer, C. (2011) Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab beyond Disease Progression in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial. Clinical Lung Cancer, 12, 407-411. http://dx.doi.org/10.1016/j.cllc.2011.05.002
[17]
Roszkowski, K., Pluzanska, A., Krzakowski, M., Smith, A.P., Saigi, E., Aasebo, U., Parisi, A., Pham Tran, N., Olivares, R. and Berille, J. (2000) A Multicenter, Randomized, Phase III Study of Docetaxel plus Best Supportive Care versus Best Supportive Care in Chemotherapy-Naive Patients with Metastatic or Non-Resectable Localized Non-Small Cell Lung Cancer (NSCLC). Lung Cancer, 27, 145-157. http://dx.doi.org/10.1016/S0169-5002(00)00094-5
